PMID: 8957955Nov 1, 1996Paper

Early identification of anthracycline cardiomyopathy: possibilities and implications

Archives of Disease in Childhood
F A Bu'LockR P Martin

Abstract

The number of survivors of childhood cancer affected by anthracycline cardiomyopathy is steadily increasing, despite efforts to limit cardiotoxicity by dose restriction. Cardiac function was evaluated prospectively in 125 children during treatment to attempt to identify individual susceptibilities to cardiotoxicity and hence any potential for treatment modification. Left ventricular shortening fraction was used as an index of cardiotoxicity. Shortening fraction declined as cumulative anthracycline dose increased, at an average rate of 1% per 100 mg/m2. Six patients (5%) developed heart failure. Twenty four patients (19%) had abnormal shortening fraction (< 30%) by the end of treatment, and their rate of fall of shortening fraction was significantly steeper throughout treatment than in patients finishing with normal function (shortening fraction > or = 30%). This differential susceptibility to cardiotoxicity was apparent from very early in treatment, interquartile ranges of the two shortening fraction groups separating at doses > 200 mg/m2. Patients at high risk of risk of important anthracycline cardiotoxicity may be identifiable early in treatment by regular and careful monitoring of shortening fraction. However, frequent asse...Continue Reading

References

Apr 1, 1978·Cancer·K R BloomM A Gribbin
Nov 1, 1979·Annals of Internal Medicine·D D Von HoffF M Muggia
Feb 1, 1977·The American Journal of Medicine·D D Von HoffF M Muggia
Apr 1, 1977·Cancer·R A MinowJ A Gottlieb
Jan 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J L SpeyerM Meyers
Sep 25, 1991·JAMA : the Journal of the American Medical Association·L J SteinherzM L Murphy
Mar 21, 1991·The New England Journal of Medicine·S E LipshultzS P Sanders
Nov 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D NielsenM Hansen
Sep 15, 1986·The American Journal of Cardiology·S T PalmeriS A Rosenberg
Aug 1, 1973·Cancer·E A LefrakJ A Gottlieb
Jan 1, 1984·Medical and Pediatric Oncology·J DearthW Crist
Dec 1, 1983·Cancer Treatment Reviews·D S AlbertsD L Woodward
Jul 16, 1981·The New England Journal of Medicine·R C YoungC E Myers
Feb 1, 1982·Annals of Internal Medicine·S S LeghaE J Freireich
Jan 1, 1995·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M G Mott

❮ Previous
Next ❯

Citations

Oct 6, 2005·Journal of Cancer Research and Clinical Oncology·W StöhrUNKNOWN German Late Effects Working Group in the German Society of Pediatric Oncology and Hematology (GPOH)
Jul 19, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L C M KremerP A Voûte
Aug 6, 2008·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Michele DomicoRichard B Mink
May 22, 2008·BMC Cancer·Veronika VelensekBerta Jereb
Mar 28, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·L C M KremerP A Voûte
Mar 20, 2003·Cancer Investigation·Sae HahmJacob J Steinberg
Sep 30, 2003·Medical and Pediatric Oncology·Livia KapustaO Daniëls
Dec 17, 2004·Pediatric Blood & Cancer·F Güçlü PinarliSehri Elbeg
Aug 11, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J BryantA Clegg
Mar 26, 2004·Anesthesia and Analgesia·Egbert HuettemannKonrad Reinhart
Nov 5, 1997·Annals of the New York Academy of Sciences·M G Mott
May 22, 2007·Pediatric Blood & Cancer·Sheila E ParkesJ R Mann
Jun 28, 2011·Pediatric Hematology and Oncology·Elif GulerAyse Balat
Nov 21, 2008·Postgraduate Medicine·Ashley SimmonsDavid Meyers
Feb 4, 2010·Pediatric Hematology and Oncology·Tamer BaysalDerya Cimen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.